The program is designed for convenience and fast access, helping patients begin treatment quickly while minimizing in-person barriers
Participants with severe obesity on the highest doses achieved up to 30% body weight reduction over two years, numbers previously only seen with bariatric surgery
Common symptoms include gastrointestinal issues such as nausea, constipation, diarrhea and heartburn
Those numbers exceed anything achieved by single or dual agonist peptides in comparable timeframes
Days six and seven, as the dose wears down before the next injection, some people notice a slight rebound in appetite and energy
Chronic inflammation is thought to play a role in many serious diseases, including cognitive decline and Alzheimers disease